Is PVLA or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -47.84% -38.33% Maplight Therapeutics N/A N/A N/A

Does the media refer more to PVLA or MPLT?

In the previous week, Palvella Therapeutics had 16 more articles in the media than Maplight Therapeutics. MarketBeat recorded 21 mentions for Palvella Therapeutics and 5 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Palvella Therapeutics' score of -0.34 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, MPLT or VERA?

Vera Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is MPLT or VERA more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Vera Therapeutics N/A -74.86% -60.18%

Does the media prefer MPLT or VERA?

In the previous week, Maplight Therapeutics had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 5 mentions for Maplight Therapeutics and 3 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.74 beat Maplight Therapeutics' score of 0.55 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MPLT or VRDN?

In the previous week, Viridian Therapeutics had 12 more articles in the media than Maplight Therapeutics. MarketBeat recorded 17 mentions for Viridian Therapeutics and 5 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Viridian Therapeutics' score of -0.03 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ZLAB or MPLT?

In the previous week, Zai Lab had 6 more articles in the media than Maplight Therapeutics. MarketBeat recorded 11 mentions for Zai Lab and 5 mentions for Maplight Therapeutics. Zai Lab's average media sentiment score of 0.56 beat Maplight Therapeutics' score of 0.55 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 3 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Maplight Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MPLT or BHVN?

Biohaven is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is MPLT or BHVN more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Biohaven N/A -866.46% -137.99%

Does the media refer more to MPLT or BHVN?

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 5 articles in the media. Biohaven's average media sentiment score of 0.55 beat Maplight Therapeutics' score of 0.55 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maplight Therapeutics (MPLT) Competitors

$12.17 -1.11 (-8.36%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$12.05 -0.12 (-0.99%)

As of 08/7/2026 07:46 PM Eastern

Compare

MPLT vs. PVLA, VERA, VRDN, ZLAB, and BHVN

Should you buy Maplight Therapeutics stock or one of its competitors? MarketBeat compares Maplight Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maplight Therapeutics include Palvella Therapeutics (PVLA), Vera Therapeutics (VERA), Viridian Therapeutics (VRDN), Zai Lab (ZLAB), and Biohaven (BHVN). These companies are all part of the "biotechnology" industry.

How does Maplight Therapeutics compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

40.1% of Palvella Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Maplight Therapeutics' return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Maplight Therapeutics	N/A	N/A	N/A

Palvella Therapeutics has higher revenue and earnings than Maplight Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	53.11	-$41.72M	-$4.83	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

In the previous week, Palvella Therapeutics had 16 more articles in the media than Maplight Therapeutics. MarketBeat recorded 21 mentions for Palvella Therapeutics and 5 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Palvella Therapeutics' score of -0.34 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics currently has a consensus price target of $209.14, suggesting a potential upside of 32.56%. Maplight Therapeutics has a consensus price target of $34.42, suggesting a potential upside of 182.80%. Given Maplight Therapeutics' higher probable upside, analysts plainly believe Maplight Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Maplight Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.00

Summary

Palvella Therapeutics beats Maplight Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Vera Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Vera Therapeutics (NASDAQ:VERA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Maplight Therapeutics' return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Vera Therapeutics	N/A	-74.86%	-60.18%

Maplight Therapeutics currently has a consensus target price of $34.42, suggesting a potential upside of 182.80%. Vera Therapeutics has a consensus target price of $84.58, suggesting a potential upside of 157.17%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Maplight Therapeutics is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.00
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Vera Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

In the previous week, Maplight Therapeutics had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 5 mentions for Maplight Therapeutics and 3 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.74 beat Maplight Therapeutics' score of 0.55 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Vera Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Maplight Therapeutics beats Vera Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Viridian Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Maplight Therapeutics has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Maplight Therapeutics' return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Viridian Therapeutics	-505.86%	-76.65%	-47.64%

Maplight Therapeutics currently has a consensus price target of $34.42, suggesting a potential upside of 182.80%. Viridian Therapeutics has a consensus price target of $38.93, suggesting a potential upside of 65.02%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Maplight Therapeutics is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.00
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Viridian Therapeutics had 12 more articles in the media than Maplight Therapeutics. MarketBeat recorded 17 mentions for Viridian Therapeutics and 5 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Viridian Therapeutics' score of -0.03 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Maplight Therapeutics has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Viridian Therapeutics	$70.85M	37.72	-$342.60M	-$3.37	N/A

Summary

Maplight Therapeutics beats Viridian Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Zai Lab had 6 more articles in the media than Maplight Therapeutics. MarketBeat recorded 11 mentions for Zai Lab and 5 mentions for Maplight Therapeutics. Zai Lab's average media sentiment score of 0.56 beat Maplight Therapeutics' score of 0.55 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	3 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Maplight Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maplight Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	5.77	-$175.54M	-$1.71	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Maplight Therapeutics' return on equity of 0.00% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Maplight Therapeutics	N/A	N/A	N/A

Zai Lab presently has a consensus target price of $40.20, suggesting a potential upside of 72.38%. Maplight Therapeutics has a consensus target price of $34.42, suggesting a potential upside of 182.80%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Maplight Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.00

41.7% of Zai Lab shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Maplight Therapeutics beats Zai Lab on 9 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Biohaven?

Maplight Therapeutics (NASDAQ:MPLT) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Maplight Therapeutics' return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Biohaven	N/A	-866.46%	-137.99%

Maplight Therapeutics currently has a consensus price target of $34.42, indicating a potential upside of 182.80%. Biohaven has a consensus price target of $21.63, indicating a potential upside of 47.40%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maplight Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.00
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 5 articles in the media. Biohaven's average media sentiment score of 0.55 beat Maplight Therapeutics' score of 0.55 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.8% of Biohaven shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biohaven is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Summary

Maplight Therapeutics beats Biohaven on 7 of the 11 factors compared between the two stocks.

Get Maplight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MPLT vs. The Competition

Export

Metric	Maplight Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$518.66M	$3.69B	$7.03B	$13.01B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.30	9.02	270.57	25.03
Price / Sales	N/A	1,294.50	599.50	86.03
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	1.20	17.61	11.21	6.43
Net Income	-$161.15M	-$13.25M	$3.45B	$348.10M
7 Day Performance	-6.53%	6.24%	4.67%	4.41%
1 Month Performance	-69.42%	-3.50%	-1.28%	-1.11%
1 Year Performance	N/A	61.28%	77.33%	23.99%

Maplight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MPLT Maplight Therapeutics	3.4432 of 5 stars	$12.17 -8.4%	$34.42 +182.8%	N/A	$518.66M	N/A	N/A	109	Insider Trade
PVLA Palvella Therapeutics	2.9959 of 5 stars	$154.91 +1.9%	$209.14 +35.0%	+285.7%	$2.18B	$42.81M	N/A	N/A	News Coverage Earnings Report Analyst Forecast Analyst Revision Gap Up
VERA Vera Therapeutics	3.1218 of 5 stars	$30.35 +1.3%	$84.58 +178.7%	+66.2%	$2.15B	N/A	N/A	40	Upcoming Earnings Gap Up
VRDN Viridian Therapeutics	3.1085 of 5 stars	$21.07 +1.1%	$38.79 +84.1%	+43.8%	$2.15B	$70.85M	N/A	50	News Coverage Earnings Report Analyst Forecast Analyst Revision Gap Up
ZLAB Zai Lab	3.4984 of 5 stars	$18.37 -0.6%	$40.00 +117.7%	-33.3%	$2.10B	$460.16M	N/A	1,784	News Coverage Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MPLT) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maplight Therapeutics (MPLT) Competitors

MPLT vs. PVLA, VERA, VRDN, ZLAB, and BHVN

How does Maplight Therapeutics compare to Palvella Therapeutics?

Summary

How does Maplight Therapeutics compare to Vera Therapeutics?

Summary

How does Maplight Therapeutics compare to Viridian Therapeutics?

Summary

How does Maplight Therapeutics compare to Zai Lab?

Summary

How does Maplight Therapeutics compare to Biohaven?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maplight Therapeutics (MPLT) Competitors

MPLT vs. PVLA, VERA, VRDN, ZLAB, and BHVN

How does Maplight Therapeutics compare to Palvella Therapeutics?

Do institutionals & insiders have more ownership in PVLA or MPLT?

Is PVLA or MPLT more profitable?

Which has stronger earnings & valuation, PVLA or MPLT?

Does the media refer more to PVLA or MPLT?

Do analysts recommend PVLA or MPLT?

Summary

How does Maplight Therapeutics compare to Vera Therapeutics?

Is MPLT or VERA more profitable?

Do analysts recommend MPLT or VERA?

Which has preferable earnings and valuation, MPLT or VERA?

Does the media prefer MPLT or VERA?

Do insiders & institutionals have more ownership in MPLT or VERA?

Summary

How does Maplight Therapeutics compare to Viridian Therapeutics?

Is MPLT or VRDN more profitable?

Do analysts rate MPLT or VRDN?

Does the media prefer MPLT or VRDN?

Which has preferable valuation & earnings, MPLT or VRDN?

Summary

How does Maplight Therapeutics compare to Zai Lab?

Does the media refer more to ZLAB or MPLT?

Which has higher earnings and valuation, ZLAB or MPLT?

Is ZLAB or MPLT more profitable?

Do analysts rate ZLAB or MPLT?

Do institutionals & insiders hold more shares of ZLAB or MPLT?

Summary

How does Maplight Therapeutics compare to Biohaven?

Is MPLT or BHVN more profitable?

Do analysts prefer MPLT or BHVN?

Does the media refer more to MPLT or BHVN?

Do insiders & institutionals hold more shares of MPLT or BHVN?

Which has stronger earnings and valuation, MPLT or BHVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools